Document Classification

Section Type: RESULTS

Text: Reductions in HbA1c with canagliflozin 100 and 300 mg versus placebo were -0. 62 % (95 % CI -0. 69, -0. 54 ; -6. 8 mmol/mol [95 % CI -7. 5, -5. 9] ; P < 0. 001) and -0. 73 % (95 % CI -0. 81, -0. 65 ; -8. 0 mmol/mol [95 % CI -8. 9, -7. 1] ; P < 0. 001) at 18 weeks and -0. 58 % (95 % CI -0. 68, -0. 48 ; -6. 3 mmol/mol [95 % CI -7. 4, -5. 2]) and -0. 73 % (95 % CI -0. 83, -0. 63 ; -8. 0 mmol/mol [95 % CI -9. 1, -6. 9]) at 52 weeks.